Europe Viral Vectors and Plasmid DNA Manufacturing Market

Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2023 to 2028)

The viral vectors and plasmid DNA manufacturing market size in Europe is anticipated to be worth USD 1210 million by 2028 from USD 286.3 million in 2023, growing at a CAGR of 25.67% from 2023 to 2028.

The growing cancer patient population in Europe primarily propels the European viral vectors and plasmid DNA manufacturing market growth. Approximately 1.9 million individuals have succumbed to cancer in the European region in 2021. Plasmid DNA therapy serves as a potential remedy for several types of cancer and has the ability to curtail cancer growth. Viral vectors, on the other hand, aid in generating an anti-tumor immune response within the body and are instrumental in transporting genes that can restore cancer cells to their normal state.

The growing number of research and development endeavors dedicated to gene therapy further boosts the European market growth. As the prevalence of genetic diseases increases in the population, gene therapy has emerged as a preferred mode of treatment. Viral vectors, particularly the adeno-associated virus, play a vital role in facilitating gene therapy and bolstering the Europe market growth. Gene therapy offers a novel approach to treating genetic diseases by replacing defective genes and holds tremendous promise in the treatment of inherited disorders, viral infections, and other maladies.

Steady progress is being made in the development of advanced viral vectors and plasmid DNA products and this trend is estimated to continue during the forecast period and drive the European market growth. Key market players and manufacturers are ramping up their investments in product manufacturing in response to the surging numbers of viral infections and novel variants. Additionally, the market is benefitting from robust support from the pharmaceutical sector, increasing government funding and significant advancements in technology. The diverse range of gene therapies being developed is also contributing to the growth of the market in Europe.

The robust support from the pharmaceutical industry, the growing funding by the European governments for research and development activities in the field of gene therapy, the favorable regulatory environment in Europe for gene therapies, strategic collaborations between key players and academic institutions and rising demand for personalized medicine accelerate the European market growth. The growing awareness and increasing acceptance of gene therapies by healthcare professionals and the European population further boost the growth rate of the European market.

The high costs associated with the processes majorly hamper the European market growth. The errors and failures during the manufacturing process are further impeding the market growth. The shortage of skilled professionals, the high cost of viral vectors and the need for proper infrastructure facilities hinder the regional market growth. The presence of alternative therapies and treatment processes is also hindering the regional market growth. To overcome these challenges, manufacturers and key players in the market must invest in research and development activities to streamline the manufacturing process and enhance its efficiency. The development of more cost-effective and reliable manufacturing methods is necessary to meet the growing demand for gene therapy.

This research report on the Europe viral vectors and plasmid DNA manufacturing market has been segmented and sub-segmented into the following categories.

By Product:

• Plasmid DNA
• Viral Vectors
• Non-viral Vectors

By Application:

• Cancers
• Inherited Disorders
• Viral Infections
• Others

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European region accounted for a substantial share of the global market in 2022 and is expected to witness a prominent CAGR during the forecast period due to the growing patient population, increasing approval of viral vector and plasmid DNA products for research purposes in the healthcare sector and an increasing number of favorable measures by the European governments to facilitate the approval process.

The UK market captured the leading share of the European market in 2022 and is expected to witness healthy growth during the forecast period. The expansion of manufacturing facilities is a major factor driving the UK market growth. Notably, ViroCell Biologics is the first clinical trial focused on viral vectors in the UK, producing various viral vectors for research purposes. Key players in the UK are also increasing their partnerships to develop plasmid DNA manufacturing.

Germany is another lucrative regional market for viral vectors and plasmid DNA manufacturing and is expected to hold a considerable share of the European market during the forecast period owing to the growing number of clinical trials being conducted in Germany. The use of viral vector manufacturing in the initial stages of clinical trials is driving the German market growth. The spread of the pandemic has further accelerated the development of plasmid DNA manufacturing in Germany, with the government increasing the number of manufacturing facilities in the region. These facilities improve autonomy and flexibility in manufacturing, with plasmid DNA being a critical component in the production of mRNA-based immunizations and treatments, as well as in various cell therapies.

KEY MARKET PLAYERS:

Lonza Group AG, Cobra Biologics Ltd, Oxford BioMedica, Novasep Holding SAS and Thermo Fisher Scientific Inc. are some of the notable companies in the Europe viral vectors and plasmid DNA manufacturing market.